Histone deacetylase 3 (HDAC3) as a novel therapeutic target in multiple myeloma

Histone deacetylases (HDACs) represent novel molecular targets for the treatment of various types of cancers, including multiple myeloma (MM). Many HDAC inhibitors have already shown remarkable anti-tumor activities in the preclinical setting; however, their clinical utility is limited due to unfavo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Minami, Jiro, Suzuki, Rikio, Mazitschek, Ralph, Gorgun, Gullu, Ghosh, Balaram, Cirstea, Diana, Hu, Yiguo, Mimura, Naoya, Ohguchi, Hiroto, Cottini, Francesca, Jakubikova, Jana, Munshi, Nikhil C., Haggarty, Stephen J., Richardson, Paul G., Hideshima, Teru, Anderson, Kenneth C.
Formato: Artigo
Idioma:Inglês
Publicado: 2013
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4165599/
https://ncbi.nlm.nih.gov/pubmed/23913134
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leu.2013.231
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares